PTLA’s presentation at the WF conference contained more than a modicum of spin, IMO, on the positioning of Betrixaban. I also think the phase-3 trial of Betrixaban for VTE prevention in acute hospitalized patients (http://www.clinicaltrials.gov/ct2/show/NCT01583218 ) is rigged.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”